Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of June 2022
Date of Report: June 23, 2022
Principal Executive Office: 117 Avenue de Luminy, 13009 Marseille, France
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves as a cover document for a press release (Exhibit 99.1) and does not contain embedded financial tables or statements.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. Specific operational or financial changes are contained within the referenced press release, which is not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document references a press release dated June 23, 2022, as the source of substantive information.
Investor Verification Checklist
- Verify the contents of Exhibit 99.1 (Press Release dated June 23, 2022) for specific corporate announcements.
- Confirm the identity of the signatory: Mondher Mahjoubi, Chairman of the Executive Board and Chief Executive Officer.
- Review the company's Form 20-F for comprehensive financial data, as this Form 6-K contains no financial figures.